Stryker Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kevin Lobo

Chief Executive Officer (CEO)

US$20.8m

Compensación total

Porcentaje del salario del CEO	6.7%
Permanencia del CEO	12yrs
Participación del CEO	0.03%
Permanencia media de la dirección	6.1yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kevin Lobo en comparación con los beneficios de Stryker?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	US$21m	US$1m	US$3b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$19m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$16m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$13m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$15m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$4b
Dec 31 2018	US$14m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$14m	US$1m	US$1b

Compensación vs. Mercado: La compensación total de Kevin($USD20.77M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD5.83M).

Compensación vs. Ingresos: La compensación de Kevin ha sido consistente con los resultados de la empresa en el último año.

CEO

Kevin Lobo (59 yo)

12yrs

Permanencia

US$20,767,847

Compensación

Mr. Kevin A. Lobo has been the Chief Executive Officer of Stryker Corporation since October 1, 2012 and serves as its President since October 01, 2021. He serves as Chairman of the Board at The Advanced Me...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Lobo	Chairman	12yrs	US$20.77m	0.026% $ 37.2m
Glenn Boehnlein	VP & CFO	8.5yrs	US$6.84m	0.0012% $ 1.6m
Viju Menon	Group President of Global Quality & Operations	6.5yrs	US$4.47m	0.0024% $ 3.4m
J. Pierce	Group President of MedSurg & Neurotechnology	6.2yrs	US$6.49m	0.015% $ 21.5m
Spencer Stiles	Group President of Orthopaedics & Spine	6.2yrs	US$6.49m	0.014% $ 19.5m
William Berry	VP & Chief Accounting Officer	3.2yrs	sin datos	0.00078% $ 1.1m
Robert Cohen	CTO and VP of Global R&D - Joint Replacement	no data	sin datos	sin datos
Alan Douville	VP, Chief Information Officer & Chief Information Security Officer	6.1yrs	sin datos	sin datos
Jason Beach	Vice President of Finance & Investor Relations	2.3yrs	sin datos	sin datos
Robert Fletcher	VP & Chief Legal Officer	5.5yrs	US$2.24m	0.0024% $ 3.5m
Dana McMahon	VP & Chief Compliance Officer	no data	sin datos	sin datos
Yin Becker	VP of Communications	5.8yrs	sin datos	0.0082% $ 11.6m

6.1yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0R2S es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Lobo	Chairman	12yrs	US$20.77m	0.026% $ 37.2m
Lisa Skeete Tatum	Independent Director	4.4yrs	US$319.25k	0.00085% $ 1.2m
Howard Cox	Director Emeritus	6.4yrs	US$38.86k	sin datos
John Brown	Chairman Emeritus	no data	US$286.99k	5.26% $ 7.4b
Ronda Stryker	Independent Director	40.8yrs	US$319.25k	4.83% $ 6.8b
Mary Brainerd	Independent Director	7.2yrs	US$334.25k	0.0015% $ 2.2m
Allan Golston	Independent Director	13.8yrs	US$334.25k	0.0039% $ 5.5m
Sherilyn S. McCoy	Lead Independent Director	6.4yrs	US$359.25k	0.00022% $ 309.8k
Rajeev Suri	Independent Director	6.4yrs	US$319.25k	0.0014% $ 1.9m
Giovanni Caforio	Independent Director	3.8yrs	US$319.25k	0.00067% $ 943.6k
Andrew Silvernail	Independent Director	10.9yrs	US$339.25k	0.0015% $ 2.1m
Rachel Ruggeri	Independent Director	less than a year	sin datos	0.000010% $ 14.1k

6.4yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 0R2S se considera experimentada (6.3 años de antigüedad promedio).

Stryker Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

VP & CFO recently sold US$6.7m worth of stock

VP & CFO recently sold US$3.3m worth of stock

Independent Director recently sold US$100m worth of stock

Insufficient new directors

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Recent updates

Treace Medical Concepts, Inc. Files Lawsuit Against Stryker Corporation and Its Subsidiary Wright Medical Technology, Inc

Stryker Corporation (NYSE:SYK) completed the acquisition of Vertos Medical Inc.

Upcoming dividend of US$0.80 per share

Stryker Corporation (NYSE:SYK) acquired NICO Corporation.

Stryker Corporation (NYSE:SYK) completed the acquisition of Care.ai inc.

Stryker Corporation (NYSE:SYK) acquired The Osteotomy Truss System (OTS) and Ankle Truss System of 4WEB Inc.

Stryker Corporation (NYSE:SYK) entered into a definitive agreement to acquire Vertos Medical Inc.

Stryker Corporation (NYSE:SYK) agreed to acquire Care.ai inc.

Second quarter dividend of US$0.80 announced

Stryker Announces Launch of Pangea Plating System

VP & CFO recently sold US$6.7m worth of stock

Stryker's Spine Guidance 5 Software Featuring Copilot Receives 510(K) Clearance from FDA

Second quarter 2024 earnings released: EPS: US$2.17 (vs US$1.94 in 2Q 2023)

Stryker Corporation (NYSE:SYK) completed the acquisition of Artelon, Inc.

Stryker Corporation to Report Q2, 2024 Results on Jul 30, 2024

Stryker Releases Lifepak 35 Monitor/Defibrillator

Stryker Corporation (NYSE:SYK) agreed to acquire Artelon, Inc.

First European Announces That Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing System

VP & CFO recently sold US$3.3m worth of stock

First quarter dividend of US$0.80 announced

Stryker Corporation Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$2.07 (vs US$1.56 in 1Q 2023)

Stryker Corporation to Report Q1, 2024 Results on Apr 30, 2024

Stryker Launches Gamma4 Hip Fracture Nailing System in Europe

Upcoming dividend of US$0.80 per share

Fourth quarter dividend of US$0.80 announced

New minor risk - Insider selling

Independent Director recently sold US$100m worth of stock

Stryker Announces the Launch of Prophecy Footprint, an Expansion of the Prophecy Surgical Planning System, Offering Comprehensive Surgical Planning Across the Entire Foot

Full year 2023 earnings released: EPS: US$8.34 (vs US$6.24 in FY 2022)

Stryker Corporation Provides Earnings Guidance for the Year 2024

Insufficient new directors

Upcoming dividend of US$0.80 per share at 1.0% yield

Stryker Corporation (NYSE:SYK) executed a binding offer to acquire Serf from SAS Menix.

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Stryker Corporation Declares Quarterly Dividend, Payable on January 31, 2024

Stryker Corporation Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.82 (vs US$2.16 in 3Q 2022)

Stryker to Showcase Q Guidance System with Spine Guidance Software

Stryker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Stryker Corporation Releases Its Next-Generation of Advanced Surgical Cameras

Stryker’S Pangea Systems Receive Food & Drug Administration Clearance

Key Executive recently sold US$1.4m worth of stock

Stryker Corporation Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$1.94 (vs US$1.73 in 2Q 2022)

Stryker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Independent Director recently sold US$139k worth of stock

Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software

Independent Director recently sold US$286k worth of stock

Stryker Corporation Declares Quarter Dividend, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.56 (vs US$0.85 in 1Q 2022)

Upcoming dividend of US$0.75 per share at 1.1% yield

Stryker’s Q Guidance System for Cranial Applications Receives FDA Clearance

Stryker Declares Quarterly Dividend, Payable on April 28, 2023

VP & CFO recently sold US$6.8m worth of stock

Full year 2022 earnings released: EPS: US$6.24 (vs US$5.29 in FY 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2023

Stryker Corporation to Report Q4, 2022 Results on Jan 31, 2023

Upcoming dividend of US$0.75 per share

Stryker Launches Citrefix™ Suture Anchor System

Stryker Corporation Declares Quarterly Dividend, Payable January 31, 2023

Independent Director recently sold US$64k worth of stock

Stryker Opens the OR of the Future for Customers to Experience Tomorrow's OR

Insider recently sold US$75k worth of stock

Now 20% undervalued after recent price drop